Big Cypress Acquisition Corp.

Status: Deal Closed
U=S+W/2 W=S@11.5
IPO Proceeds, $M $115.00M
IPO Date Jan 12, 2021
CEO Samuel J. Reich
Left Lead Ladenburg Thalmann
IPO Cash in Trust 101.0%
SPAC Tenor 15+(3*2)
IPO Sector Healthcare

Life sciences

IPO Geography Global
Target Company SAB Biotherapeutics
Deal Announced Jun 22, 2021
Deal Size, $M $325.38M
Deal Sector Healthcare
Deal Geography US/Canada
SEC Filings www.sec.gov
Approval Vote Oct 20, 2021
Amendment Vote TBD
Closing Date Oct 22, 2021
Formerly BCYP SABS SABSW

Sign up for Free Trial

No credit card required

Sign in for more on Big Cypress Acquisition Corp.:

  • Structure and cap table
  • 5 directors & officers
  • 23 filings and events
  • 2 underwriters
  • 3 deal advisors
  • 2 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Samuel J. Reich 45 CEO, CFO and Director
Jeffrey G. Spragens 70 Chairman
James Martin 54 Director
Ilan Katz 48 Director
Stephen D. Collins, MD, PhD. 68 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Ladenburg Thalmann Joint BR 9,000,000 units
Brookline Capital Markets Joint BR 1,000,000
10,000,000 units
Up-Front UW fee 1.33 %
Deferred UW fee 3.67 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 23 filings.

Shareholders

Sign in to view shareholders 13F filing data.